Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Depreciation & Amortization (CF) (2016 - 2025)

Ultragenyx Pharmaceutical has reported Depreciation & Amortization (CF) over the past 10 years, most recently at $8.8 million for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) fell 7.88% to $8.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $35.0 million through Dec 2025, down 2.78% year-over-year, with the annual reading at $35.0 million for FY2025, 2.78% down from the prior year.
  • Depreciation & Amortization (CF) was $8.8 million for Q4 2025 at Ultragenyx Pharmaceutical, up from $8.6 million in the prior quarter.
  • Over five years, Depreciation & Amortization (CF) peaked at $9.5 million in Q4 2024 and troughed at $3.1 million in Q2 2021.
  • The 5-year median for Depreciation & Amortization (CF) is $6.3 million (2023), against an average of $6.4 million.
  • Year-over-year, Depreciation & Amortization (CF) skyrocketed 68.93% in 2024 and then decreased 7.88% in 2025.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $3.5 million in 2021, then soared by 40.27% to $5.0 million in 2022, then skyrocketed by 65.66% to $8.2 million in 2023, then increased by 16.12% to $9.5 million in 2024, then dropped by 7.88% to $8.8 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Depreciation & Amortization (CF) are $8.8 million (Q4 2025), $8.6 million (Q3 2025), and $8.6 million (Q2 2025).